Treatment of chronic kidney disease

Jeffrey M. Turner, Carolyn Bauer, Matthew K. Abramowitz, Michal L. Melamed, Thomas H. Hostetter

Research output: Contribution to journalReview article

91 Scopus citations

Abstract

Treatment of chronic kidney disease (CKD) can slow its progression to end-stage renal disease (ESRD). However, the therapies remain limited. Blood pressure control using angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) has the greatest weight of evidence. Glycemic control in diabetes seems likely to retard progression. Several metabolic disturbances of CKD may prove to be useful therapeutic targets but have been insufficiently tested. These include acidosis, hyperphosphatemia, and vitamin D deficiency. Drugs aimed at other potentially damaging systems and processes, including endothelin, fibrosis, oxidation, and advanced glycation end products, are at various stages of development. In addition to the paucity of proven effective therapies, the incomplete application of existing treatments, the education of patients about their disease, and the transition to ESRD care remain major practical barriers to better outcomes.

Original languageEnglish (US)
Pages (from-to)351-362
Number of pages12
JournalKidney international
Volume81
Issue number4
DOIs
StatePublished - Feb 2 2012

Keywords

  • chronic kidney disease
  • chronic renal disease
  • chronic renal insufficiency

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Treatment of chronic kidney disease'. Together they form a unique fingerprint.

  • Cite this